FORM PTO-1449

UST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

239/102 **APPLICANT:** **SERIAL NO.**

09/216,062

Guo, Yajun **FILING DATE:**

December 18, 1998

ATTY. DOCKET

GROUP: JUN 0 9 1999 1643-164CP

900

JUN 0 8 W	199 C		,	December 16,	1,00	TECH	CENTER 1600/29
EXAMBADE	ST.		·U.S. F	PATENT DOCUMENTS			
EXAMIRADE INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
mo	AA	5,669,394	9/23/97	Bergey et al.	128	750	12/22/94>
no	AB	5,789,215	8/4/98	Berns et al.	.435	172.3	8/7/97
$\sim \sim$	AC	5,591,828	1/7/97	Bosslet et al.	530	387.3	9/29/94-
MO	AD.	5,635,602	6/3/97	Cantor et al.	1530	391.1	8/13/93
NW	AE	4,697,600	10/6/87	Cardenas et al.	428	753	6/4/86
ms	AF	5,241,969	9/7/93	Carson et al.	1 28	753	6/10/92
MO	AG 💒	5,582,996	12/10/96	Curtis	435	7.1	5/27/94
MS	AH	4,989,614	2/5/91	Dejter, Jr. et al.	128	752	2/23/88
mo	AI	5,060,658	10/29/91	Dejter, Jr. et al.	128	753	7/30/90
med	AJ '	5,635,600	6/3/97	Fanger et al.	530	387.3	12/27/94
ruc	AK	5,484,596	1/16/96	Hanna, Jr. et al.	424	277.1	11/1/93
CVM C	AL	4,844,893	7/4/89	Honsik et al.	424	85.8	10/7/86
MO	AM,	5,141,736	8/25/92	Iwasa et al.	530	387.3	12/27/89
Map	AN-	5,637,481	6/10/97	Ledbetter et al.	435	69.6	9/13/93
NW	AO	5,770,429	6/23/98	Lonberg et al.	435	240.2	10/10/95
W	AP	5,814,318	9/29/98	Lonberg et al	424	184.1	7/22/93
me	\mathcal{D}_{AQ}	4,605,011	8/12/86	Naslund	128	752	3/13/84
mD	AR.	5,292,668	3/8/94	Paulus	436	547	12/5/90
M	AS	5,530,101	6/25/96	Queen et al.	530	387.3	12/19/90
MO	AT	5,693,762	12/2/97	Queen et al.	-530	387.3	6/7/95
mo	AU	5,655,541	8/12/97	Vattuone	128	749	12/29/94
MD'	ĀV '	5,601,819	2/11/97	Wong et al.	424	136.1	9/14/94

DATE CONSIDERED 3 **EXAMINER:**

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

FORM PTO-1449				ATTY. DOCKE 239/102		SERIAL NO. 09/216,062	REC	EIV
	TENTS AND OTHER ITEM ORMATION DISCLOSURI			APPLICANT: Guo, Yajun				0 9 1
	Subse several sheets if ne			FILING DATE: December 18, 1		GROUP:	ÉH CEN	TER 16(
JUN 0 8 1999	Ž	FOREIG	N PATENT D	OCUMENTS .		· (
EXAMINATE ADEMAN	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUB CLASS	TRANS YES	LATION NO
MAN AW	WO 95/16775	22.06.95	PCT					
MO AX	WO 98/24884	11.06.98	PCT					

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
þ	MD	AZ	Vaughan, Tristan J. et al., "Human antibodies by design," Nature Biotechnology, 16:535-539 (1998)						
2	WY) BA	Reiter, Yoram et al., "Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fv fragments," <i>Nature Biotechnology</i> , 14:1239-1245 (1996)						
3	w	BB	Guo, Ya-Jun et al., "Effective tumor vaccines generated by <i>in vitro</i> modification of tumor cells with cytokines and bispecific monoclonal antibodies," <i>Nature Medicine</i> , 451-455 (April, 1997)						
4	NO	BC	Nestle, Frank O. et al., "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells," Nature Medicine (4) 328-332 (1998)						
5	M	BD	Mayordomo, J. I. et al., "Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity," <i>Nature Medicine</i> , 1:1297-1302 (1995)						
þ	MA	BE	Ostrand-Rosenberg, Suzanne, "Tumor immunotherapy: the tumor cell as an antigen-presenting cell," Current Opinion in Immunology, 6:722-727 (1994)						
7	MO	BF	Panettieri, Jr., Reynold A. et al., "Activation of cAMP-Dependent Pathways in Human Airway Smooth Muscle Cells Inhibits TNF-α-Induced ICAM-1 and VCAM-1 Expression and T Lymphocyte Adhesion," <i>The Journal of Immunology</i> , 154:2358-2365 (1995)						
8	NO	BG	Holliger, Philipp et al., "Antibodies come back from the brink," Nature Biotechnology, 16:1015-1016 (1998)						
9	MO	ВН	Bubenik, J. et al., "Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2," <i>Immunology Letters</i> , 23:287-292 (1990)						
10	4	BI /	Kubin, Marek et al., "Interleukin 12 Synergizes with B7/CD28 Interaction in Inducing Efficient Proliferation and Cytokine Production of Human T Cells," J. Exp. Med., 180:211-222 (1994)						
(1	MO	BJ ~	Li, Yiwen et al., "Costimulation by CD48 and B7-1 Induces Immunity against Poorly Immunogenic Tumors," J. Exp. Med., 183:639-644 (1996)						
12	not) BK	Johnston, Janet V. et al., "B7-CD28 Costimulation Unveils the Hierarchy of Tumor Epitopes Recognized by Major Histocompatibility Complex Class I-restricted CD8 Cytolytic T Lymphocytes," J. Exp. Med., 183:791-800 (1996)						
13	W)	BL	Haddada, H. et al., "Tumorigenicity of hamster and mouse cells transformed by adenovirus types 2 and 5 is not influenced by the level of class I major histocompatibility antigens expressed on the cells," <i>Proc. Natl. Acad. Sci. USA</i> , 83:9684-9688 (1986)						
14	M	ВМ	. Gilliland, Lisa K. et al., "Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells," Proc. Natl. Acad. Sci. USA, 85:7719-7723 (1988)						
15	un	BN	Dranoff, Glenn et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity," <i>Proc. Natl. Acad. Sci. USA</i> , 90:3539-3543 (1993)						
lu	MD	ВО	Chen, Lieping et al., "Costimulation of Antitumor Immunity by the B7 Counterreceptor for the T Lymphocyte Molecules CD28 and CTLA-4," Cell, 71:1093-1102 (1992)						

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or	not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not	considered. Include a copy of this form with next
communication to applicant	

- AY EP 0 885-614-A2

	FORM PTO-1449		ATTY. DOCKET	SERIAL NO.			
	LIST OF PATE	ENTS AND OTHER ITEMS FOR APPLICANT'S	239/102 09/216,062 APPLICANT:				
		RMATION DISCLOSURE STATEMENT	Guo, Yajun				
	VILEY		FILING DATE:	GROUP:			
		(Us several sheets if necessary)	December 18, 1998	2643 (CHY			
(JUN 0 8 1999 C	Pagker Siyaguhramanian et al. "Constitutiva annuas	:fD7	11			
17	BES	Baskar, Sivasubramanian et al., "Constitutive express truncated major histocompatibility complex class II m	nolecules," Proc. Natl. Acad. Se	ci. USA, 90:5687-5690 (1993)			
18	MADENBO	Armstrong, Todd D. et al., "Major histocompatibility antigen and are potent inducers of tumor-specific imm	complex class II-transfected tu nunity <i>Proc. Natl. Acad. Sci. U.</i>	mor cells present endogenous SA. 94:6886-6891 (1997)			
19	M BR	Tsioulias, George J. et al., "Expression of HLA Class Mucosa of the Colon," Cancer Research, 53:2374-23	I Antigens in Sporadic Adenoi	mas and Histologically Normal			
20	MY) BS	Johnstone, Alan et al., "Immunochemistry in Practice,	Chapter 2 np 30-47 (Blackw	ell New York 2d ed \ (1988)			
ZI	₩ BT	Nabel, Gary J. et al., "Direct Gene Transfer for Treatr Sciences, 772:227-231 (1995)	ment of Human Cancer," Annai	's New York Academy of			
22	MD BU -	Allison, James P. et al., "Manipulation of costimulato Opinion in Immunology., 7:682-686 (1995)	ry signals to enhance antitumo	r T-cell responses," Current			
23	(a)	Jurianz, Katrin et al., "Adhesive function of Newcastl	e disease virus hemagglutinin i	n tumor-host interaction,"			
24	BV	International Journal of Oncology, 7:539-545 (1995) Hock, Hanno et al., "Vaccinations with Tumor Cells (
_	BW BW	Effectivity not Superior to a Classical Adjuvant," Can Mattsson, Ragnar et al., "In Vivo Treatment with Inte					
2/2	BX BX	Strong Expression of Major Histocompatibility Comp in Extra-Embryonic Tissues," <i>Biology of Reproduction</i>	lex Class I and II Molecules in	Uterus and Decidua But Not			
74	NAA O	Wang, Jianli et al., "Eliciting T Cell Immunity Agains	st Poorly Immunogenic Tumors				
	BY	Dendritic Cell-Tumor Fusion Vaccines," <i>The Journal</i> Vaughan, Tristan J. et al., "Human Antibodies with St					
27	HO BZ	immunized Phage Display Library," Nature Biotechno	ology, 14:309-314 (1996)				
28	Asher, A. L. et al., "Murine Tumor Cells Transduced with the Gene for Tumor Necrosis Factor-α; Evidence for Paracrine Immune Effects of Tumor Necrosis Factor against Tumors," The Journal of Immunology, 146:3227-						
	CA	3234 (1991)					
29	CB CB	Yang, Guchen et al., "Antitumor Immunity Elicited by CD28/CTLA-4 Costimulatory Molecules," <i>The Journ</i>	y Tumor Cells Transfected with al of Immunology, 154:2794-2	h B7-2, a Second Ligand for 800 (1995)			
30	NO CC	Toffaletti, Dena L. et al., "Augmentation of Syngeneior Hybrids," <i>The Journal of Immunology</i> , 130:2982-2980		Semiallogeneic Cell			
31	hup co	Ostrand-Rosenberg, Suzanne et al., "Rejection of Mou Genes," The Journal of Immunology, 144:4068-4071	use Sarcoma Cells After Transf	fection of MHC Class II			
32	MAD CE	MacLean, James A. et al., "Anti-CD3: Anti-IL-2 Rece Immunology, 150:1619-1628 (1993)		ntibody," The Journal of			
	CE	Blazar, Bruce R. et al., "In Vivo Blockade of CD28/C	TLA4: B7/BB1 Interaction Wi	th CTLA4-Ig Reduces Lethal			
33	WQ_{CF}	Murine Graft-Versus-Host Disease Across the Major 1 83:3815-3825 (1994)	Histocompatibility Complex B	arrier in Mice," Blood,			
34	\wp \wp	Gansbacher, Bernd et al., "Retroviral Vector-mediated Potent and Long Lasting Antitumor Immunity," Canc					
		Bakker, Alexander B. H. et al., "Generation of Antime	elanoma Cytotoxic T Lymphoc	ytes from Healthy Donors			
35	Mest CH	after Presentation of Melanoma-associated Antigen-de Research, 55:5330-5334 (1995)	erived Epitopes by Dendritic C	ells in Vitro," Cancer			
3le	IVO CI	Ockert, Detlef et al., "Newcastle Disease Virus-infector Active Specific Immunotherapy of Resected Colorect					
39	Rup CJ	Elliott, Bruce E. et al., "Perspectives on the Role of M	IHC Antigens in Normal and M	Malignant Cell Development,"			
38	74.	Advances in Cancer Research, 53:181-245 (1989) Hellstrom, Karl Erik et al., "Can Co-stimulated Tumo	r Immunity be Therapeutically	Efficacious?," Immunological			
Į	EXAMINER: DATE CONSIDERED:						
	Maname Dimo 6/3/10						
		tial if reference is considered, whether or no					
	Draw line through citation if not in conformance and not considered. Include a copy of this form with next						
_	communication to applicant						
I	Information Disclosure Statement – Section 9 PTO-1449 Page 3 of 6						

. 4		_				
FORM PTO-1449		ATTY. DOCKET	SERIAL NO.			
· /	—	239/102	09/216,062			
	NTS AND OTHER ITEMS FOR APPLICANT'S	APPLICANT:				
INFO	RMATION DISCLOSURE STATEMENT	Guo, Yajun				
IPE		FILING DATE:	GROUP: (a)			
10 5	(Use several sheets if necessary)	December 18, 1998	1645 644			
JUN 0 8 1998 CIE	von Hoegen, Paul et al., "Modification of Tumor Cell Immunology, 126:80-90 (1990)	s by a Low Dose of Newcastle	Disease Virus," Cellular			
TRADENCM	Linsley, Peter S. & Jeffrey A. Ledbetter, "The Role of Annu. Rev. Immunol., 11:191-212 (1993)					
MD CN	Hock, Hanno et al., "Interleukin 7 Induces CD4+ T C 1298 (1991)		-			
ly Oco	Colombo, Mario P. et al., "Granulocyte Colony-stimu Murine Adenocarcinoma In Vivo," J. Exp. Med., 173		uppresses Tumorigenicity of a			
CP Donnelly, John J. et al., "Immunization with DNA," Journal of Immunological Methods, 176:145-15						
IND CQ	Young, James W. et al., "Dendritic Cells as Adjuvants for Class I Major Histocompatibility Complex-restrict Antitumor Immunity," J. Exp. Med., 183:7-11 (1996)					
CR CR	Zitvogel, Laurence et al., "Therapy of Murine Tumor T Cells, B7 Costimulation, and T Helper Cell 1-assoc					
THO CS	Celluzzi, Christina M. et al., "Peptide-pulsed Dendrit Tumor Immunity," J. Exp. Med., 183:283-287 (1996)	ic Cells Induce Antigen-specif	ic, CTL-mediated Protective			
MA CT	Caux, Christophe et al., "B70/B7-2 Is Identical to CD on Human Dendritic Cells," J. Exp. Med., 180:1841-	86 and Is the Major Functiona	l Ligand for CD28 Expressed			
NW) CU	Hurtado, José C. et al., "Potential Role of 4-1BB in T Molecule CD28," The Journal of Immunology, 155:3	Cell Activation; Comparison	with the Costimulatory			
NO cv	Porgadór, Angel et al., "Interleukin 6 Gene Transfection into Lewis Lung Carcinoma Tumor Cells Suppresses the Malignant Phenotype and Confers Immunotherapeutic Competence against Parental Metastatic Cells," Cancer Research, 52:3679-3686 (1992)					
AND CW	Reeves, Mark E. et al., "Retroviral Transduction of Human Dendritic Cells with a Tumor-associated Antigen Gene," Cancer Research, 56:5672-5677 (1996)					
Le CX	Luboldt, Hans-Joachim et al., "Selective Loss of Human Leukocyte Antigen Class I Allele Expression in					
MD CY	Bode, Christoph et al., "Antibody-directed Fibrinolysis," The Journal of Biological Chemistry, 264:944-948					
110	Hathcock, Karen S. et al., "Identification of an Alternative CTLA-4 Ligand Costimulatory for T Cell Activation,					

DH	Expression in Human Epidermal Keratinocytes," J. Invest. Dermatol., 103:791-796 (1994)
EXAMINER:	DATE CONSIDERED: 21/6
EXAMINER: Init	ial if reference is considered, whether or not citation is in conformance with MPEP 609;
Draw line through	gh citation if not in conformance and not considered. Include a copy of this form with next
communication	to applicant

Quo, Yajun et al., "Effective Tumor Vaccine Generated by Fusion of Hepatoma Cells with Activated B Cells,"

Pownsend, Sarah E. & James P. Allison, "Tumor Rejection After Direct Costimulation of CD8+ T Cells by B7-

Leach, Dana R. et al., "Enhancement of Antitumor Immunity by CTLA-4 Blockade," Science, 271:1734-1736

Renner, Christoph et al., "Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human

Allison, James P. & Matthew F. Krummel, "The Yin and Yang of T Cell Costimulation," Science, 270:932-933

Ikeda, Mitsunori et al., "Suppressive Effect of Antioxidants on Intercellular Adhesion Molecule-1 (ICAM-1)

Trojan, Jerzy et al., "Treatment and Prevention of Rat Glioblastoma by Immunogenic C6 Cells Expressing

Science, 262:905-907 (1993)

Science, 263:518-520 (1994)

T Cells," Science, 264:833-835 (1994)

Chang et al., Gastroenterology, 112(4):A546 (1997)

Transfected Melanoma Cells," Science, 259:368-370 (1993)

Antisense Insulin-Like Growth Factor I RNA," Science, 259:94-96 (1993)

CZ

DB

DC

DD

DE

DF

DG

D DH

(1995)

58

FORM PTO-1449	•	ATTY. DOCKET	SERIAL NO.	
JA* LIST OF DATE	ENTS AND OTHER ITEMS FOR APPLICANT'S	239/102 APPLICANT:	09/216,062	
	RMATION DISCLOSURE STATEMENT			
TO TO	RMATION DISCLOSURE STATEMENT	Guo, Yajun	CROUD	
(4.5.E.)	(Use several sheets if necessary)	FILING DATE:	GROUP:	
_/ <u>C</u> ;	Ose several silects if flecessary)	December 18, 1998	1,1643 [694	
- PER R	<u> </u>		1	
DI NULL	Hoogenboom, Hennie R. et al., "Antibody phage dis 20 (1998)			
NE TRADEMARK	Golumbek, Paul T. et al., "Treatment of Established Interleukin-4," Science, 254:713-716 (1991)	Renal Cancer by Tumor Cel	ls Engineered to Secrete	
MC DK	Freeman, Gordon J. et al., "Cloning of B7-2: A CTL Proliferation," Science, 262:909-911 (1993)	· -		
DL DL	Wallich, R. et al., "Abrogation of metastatic property following H-2 gene trasfection," <i>Nature</i> , 315:301-31	.5 (1985)		
MD DM	Shahinian, Arda et al., "Differential T Cell Costimul 261:609-612 (1993)	atory Requirements in CD28	3-Deficient Mice," Science,	
MOD DN	Murphy, Erin E. et al., "B7 and Interleukin 12 Coop Helper Clones That Are Unresponsive to B7 Costim	ulation," <i>J. Exp. Med.</i> , 180:2	23-231 (1994)	
DO	Paglia, Paola et al., "Murine Dendritic Cells Loaded Lymphocytes against Tumor Antigen In Vivo," J. E.	In Vitro with Soluble Proteinsp. Med., 183:317-322 (1996)	n Prime Cytotoxic T	
DP	Luster, Andrew D. et al., "IP-10, a -C-X-C- Chemok In Vivo," <i>J. Exp. Med.</i> , 178:1057-1065 (1993)		•	
Porgador, Angel et al., "Bone Marrow-generated Dendritic Cells Pulsed with a Class I-restricted Peptide Are Potent Inducers of Cytotoxic T Lymphocytes," J. Exp. Med., 182:255-260 (1995)				
Seder, Robert A. et al., "CD28-mediated Costimulation of Interleukin 2 (IL-2) Production Plays a Critical Role in T Cell Priming for IL-4 and Interferon γ Production," The Journal of Experimental Medicine, 179:299-304 (1994)				
MIDDS	Gong, Jianlin et al., "Induction of antitumor activity cells," <i>Nature Medicine</i> , 3(5):558-561 (1997)	by immunization with fusion	ns of dendritic and carcinoma	
PLD DT	Melero, Ignacio et al., "Monoclonal antibodies agair tumors," <i>Nature Medicine</i> , 3:682-685 (1997)	ast the 4-1BB T-cell activation	on molecule eradicate éstablishe	
MOD DU	Hsu, Frank J. et al., "Vaccination of patients with B-cells," <i>Nature Medicine</i> , 2(1):52-58 (1996)	cell lymphoma using autolog	gous antigen-pulsed dendritic	
\mathcal{W} DV	Linsley, Peter S. et al., "CTLA-4 Is a Second Recept 174:561-569 (1991)	tor for the B Cell Activation	Antigen B7," J. Exp. Med.,	
MO DW	DeBenedette, Mark A. et al., "Role of 4-1BB Ligand Upregulation on M12 B Lymphomas by cAMP," J.			
NAO DX	June, Carl H. et al., "The B7 and CD28 receptor fam			
MY DY	Boczkowski, David et al., "Dendritic Cells Pulsed w Vivo," J. Exp. Med., 184:465-472 (1996)			
MQ DZ	Tykocinski, Mark L. et al., "Antigen-Presenting Cel. (1996)			
M EA	Ulevitch, Richard J. et al., "Hyperexpression of Intel Reorganization of the Cytoskeleton," American Journ	nal of Pathology, 139:287-2	96 (1991)	
MV EB	Saito, Ichiro et al., "Expression of Cell Adhesion Me Syndrome," Journal of Clinical Laboratory Analysis	, 7:180-187 (1993)		
KWO EC	Zöller et al., "Interleukin-1 Production by Transform Cell-Mediated Anti-Tumor Response," Intl. J. Canc	er, 50:450-457 (1992)		
My ED.	Darlington, Gretchen J. et al., "Expression of Liver I the National Cancer Institute, 64:809-815 (1980)			
MaO	Restifo, Nicholas P. et al., "Molecular Mechanisms Immunogenetherapy and the Cell Biology of Major Immunotherapy, 14:182-190 (1993)			

EXAMINER: Mariane Dir	DATE CONSIDERED:	x131/w
EXAMINER: Initial if reference is considered, whether of	or not citation is in co	onformance with

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

4	و بره		·						
	FORM PTC)-1449 a		ATTY. DOCKE?	SERIAL NO. 09/216,062				
	IJST Ĉ	OF PATE	NTS AND OTHER ITEMS FOR APPLICANT'S	APPLICANT:					
		INFOR	MATION DISCLOSURE STATEMENT	Guo, Yajun					
				FILING DATE:	GROUPE A A				
	OIP	E ((Use several sheets if necessary)	December 18, 1998	1642 (1044				
'	70	2			10 1				
Holliger, Philipp et al., "Retargeting serum immunoglobulin with bispecific diabodies," Nature Biotech									
م	COLUMN TO	Merchant, A. Margaret et al., "An efficient route to human bispecific IgG," Nature Biotechnology, 16:677-681 (1998)							
37	TRADE	EH	McGuinness, Brian T. et al., "Phage diabody repertoir fragments," Nature Biotechnology, 14:1149-1154 (199		pers of bispecific antibody				
88		EI	Liu, Margaret, "Transfected human dendritic cells as o						
89	2	EJ	Tepper, Robert I. et al., "Murine Interleukin-4 Display (1989)						
10	Ng)	EK	Fearon, Eric R. et al., "Interleukin-2 Production by Tu an Antitumor Response," <i>Cell</i> , 60:397-403 (1990)	· · · · · · · · · · · · · · · · · · ·					
11	and	EL	Ertel, Christian et al., "Viral hemagglutinin augments <i>Immunol.</i> , 23:2592-2596 (1993)						
12	no	EM D	Willems, Fabienne et al., "Interleukin-10 inhibits B7 a monocytes," Eur. J. Immunol., 24:1007-1009 (1994)						
13	Alderson, Mark R. et al., "Molecular and biological characterization of human 4-1BB and its ligand," Eur. J. Immunol., 24:2219-2227 (1994)								
M	MO	EO	Green, Jonathan M. et al., "Absence of B7-Dependent (1994)	-	• •				
15	mo	EP	Molecular Biology of the Cell, pp. 47-58 & pp. 276-33 NY & London						
14	Mas	EQ	Huang, Alex Y. C. et al., "Role of Bone Marrow—De Antigens," Science, 264:961-965 (1994)	rived Cells in Presenting MH	C Class I—Restricted Tumor				
		ER							
		ES							
		ET							
		EU	•						
		EV							
		EW							
		EX							
		EY							
		EZ							
		FA							
		FB							
	l .	I							

EXAMINER:	6	\sim	DATE CONSIDE	RED:
)	1 narane	1200	DATE CONSIDE	:// <i>C</i> D
EXAMINER:	Initial if reference is co	nsidered, whether	or not citation i	s in conformance with MPEP 609;
Draw line thr	ough citation if not in o	conformance and n	ot considered.	Include a copy of this form with next
communicati	on to applicant			